10-Q: Myriad Genetics Reports Q2 Loss Amid $317M Impairment

Myriad Genetics reported a significant net loss in the second quarter of 2025, primarily driven by a $316.7 million goodwill and intangible asset impairment charge, despite slight revenue growth.

Summary

• Reported a net loss of $330.5 million for the three months ended June 30, 2025, significantly wider than the $36.7 million loss in the prior year period.
• Recognized a substantial goodwill and long-lived asset impairment charge of $316.7 million in the second quarter of 2025, compared to $11.6 million in the prior year.
• Revenue for the three months ended June 30, 2025, increased slightly to $213.1 million from $211.5 million in the same period last year.
• Hereditary Cancer revenue grew by $4.8 million (5.25%) to $96.3 million, driven by a 7% increase in volume.
• Prenatal revenue increased by $3.2 million (7.21%) to $47.6 million, despite an 8% decrease in volume, due to a 17% increase in average revenue per test.
• Pharmacogenomics revenue decreased by $5.2 million (12.09%) to $37.8 million, primarily due to a 16% decrease in average revenue per test, impacted by UnitedHealthcare's coverage changes for the GeneSight test.
• Tumor Profiling revenue decreased by $1.2 million (3.68%) to $31.4 million, mainly due to the sale of the EndoPredict business in August 2024.
• Cash and cash equivalents decreased by $28.0 million to $74.4 million as of June 30, 2025, from $102.4 million at December 31, 2024.
• Net cash used in operating activities increased to $29.9 million for the six months ended June 30, 2025, compared to $16.0 million in the prior year period.
• Secured a new $200 million term loan credit facility with OrbiMed, with an initial $125 million funded on July 31, 2025, used in part to repay the existing ABL Facility of $60.2 million.

Sentiment

Score: 2

Explanation: The significant goodwill and intangible asset impairment charges, leading to a substantial net loss and increased cash burn from operations, indicate severe financial underperformance and a re-evaluation of asset values. While new financing provides liquidity and new product developments are positive, they are heavily overshadowed by the magnitude of the financial setbacks and ongoing revenue challenges in a key segment.

Positives

• Hereditary Cancer revenue increased by 5.25% for the quarter, driven by a 7% volume increase.
• Prenatal revenue grew by 7.21% for the quarter, supported by a 17% increase in average revenue per test.
• Cost of revenue decreased by 4.81% for the quarter, primarily due to reductions in the cost of laboratory reagents and supplies.
• Launched early access of FirstGene Multiple Prenatal Screen in June 2025, a new prenatal genetic risk assessment.
• Presented positive data for the Precise MRD test in May 2025, demonstrating 100% baseline detection of circulating tumor DNA (ctDNA) and lead time in detecting recurrence.
• Earned the Great Place to Work Certification for the third consecutive year in July 2025.
• Expects to receive a tax refund of approximately $13 million, including interest, during 2025 related to CARES Act claims.

Negatives

• Reported a significant net loss of $330.5 million for the three months ended June 30, 2025, compared to a $36.7 million loss in the prior year.
• Incurred a substantial goodwill and long-lived asset impairment charge of $316.7 million, reflecting a sustained decline in market capitalization and downward revisions to forecasts.
• Pharmacogenomics revenue decreased by 12.09% for the quarter and 16.0% for the six months, primarily due to UnitedHealthcare's policy change regarding GeneSight test coverage.
• Total volume decreased by 1% for the three months and 0.13% for the six months ended June 30, 2025.
• Cash used in operating activities increased to $29.9 million for the six months ended June 30, 2025, indicating higher cash burn.
• Total assets decreased by $350.3 million, largely due to the impairment charges on goodwill and intangible assets.

Risks

• Sales and profit margins of existing tests may decline.
• Inability to operate the business on a profitable basis.
• Failure to achieve certain revenue growth targets or generate sufficient revenue from existing or new tests.
• Changes in governmental or private insurers' coverage and reimbursement levels, including UnitedHealthcare's policy changes for multi-gene panel pharmacogenetic tests like GeneSight.
• Increased competition and development of new competing tests.
• Inability to develop or achieve commercial success for additional tests in a timely manner.
• Inability to secure additional financing on favorable terms, if needed.
• Termination or inability to maintain licenses to technology underlying tests.
• Delays or problems with operating laboratory testing facilities.
• Public concern over genetic testing in general or specific tests.
• Regulatory requirements or enforcement changes in the U.S. and foreign countries.
• Inability to obtain new corporate collaborations or acquire/develop new technologies or businesses.
• Inability to successfully integrate and derive benefits from licensed, acquired, or developed technologies/businesses.
• Inaccuracy of projections or estimates about the potential market opportunity for products.
• Inability to protect proprietary technologies or patent-infringement claims/challenges.
• Changes in intellectual property laws or enforcement.
• Security breaches, loss of data, and other disruptions, including cyberattacks.
• Inability to keep pace with rapid technology changes in the industry.
• Inability to comply with financial or operating covenants under credit or lending agreements.
• Risks related to current and future investigations, claims, or lawsuits, including derivative claims and product/professional liability claims.

Future Outlook

Pharmacogenomics revenues are expected to continue to be negatively impacted by UnitedHealthcare's change in GeneSight test coverage for the remainder of fiscal year 2025 and thereafter. Existing capital resources, including cash, expected cash flows from operations, and the new debt financing, are believed to be sufficient to meet projected operating requirements for at least the next 12 months. The company remains committed to disciplined cost management while maintaining investments in key strategic areas like research and development. The recently enacted 'One Big Beautiful Bill Act' is not expected to have a material impact on current or net deferred tax balances.

Management Comments

• "We believe there are significant growth opportunities in addressing urgent healthcare needs through innovative molecular diagnostic and precision testing services."
• "Our strategy is focused on three strategic pillars."
• "We plan to drive accelerated growth and profitability by focusing on the Cancer Care Continuum, or CCC market."
• "We aim to grow our Prenatal Health and Mental Health revenues at or above market growth."
• "We plan to complement the revenue growth drivers outlined above with an enhanced focus and commitment on delivering sustained, profitable growth."
• "We remain committed to disciplined cost management while maintaining investments in key strategic areas, such as research and development."
• "We believe that our existing capital resources will be sufficient to meet our projected operating requirements for at least the next 12 months."
• "We expect that Pharmacogenomics revenues during the remainder of fiscal year 2025 and thereafter will continue to be negatively impacted by UnitedHealthcare's change in GeneSight test coverage under its commercial and individual exchange benefits plans."
• "We expect to generate cash inflows in the near future."

Industry Context

The company operates in the molecular diagnostic testing and precision medicine industry, focusing on assessing disease risk, progression, and guiding treatment decisions across various medical specialties. It emphasizes significant growth opportunities within the Cancer Care Continuum (CCC) market and aims to expand its Prenatal Health and Mental Health revenues. The industry faces challenges related to evolving healthcare policies and reimbursement rates, as evidenced by UnitedHealthcare's policy change negatively impacting the company's pharmacogenomics segment. The company is also investing in new technologies like molecular residual disease (MRD) testing, indicating a focus on high-growth segments within the cancer diagnostics space.

Comparison to Industry Standards

• The MONSTAR-SCREEN-3 prospective study data for the Precise MRD test demonstrated 100% baseline detection of circulating tumor DNA (ctDNA) across tumor types, including those traditionally challenging to assess.
• The Precise MRD test showed detection of tumor fractions as low as 0.0001% and a lead time in detecting recurrence compared to imaging.
• The company believes this data highlights the potential importance of its ultra-sensitive Precise MRD test compared to first-generation MRD tests, suggesting a competitive advantage in sensitivity and early detection.

Management Changes

Corporate Governance

Legal Proceedings

• Received a civil investigative demand from the U.S. Department of Justice in June 2023 regarding alleged False Claims Act violations concerning remuneration to physicians at Carolina Urology Partners, PLLC.
• A qui tam complaint, filed November 3, 2022, was unsealed on January 22, 2025, against Carolina Urology Partners, PLLC, and certain physicians, and the Company and certain former employees, alleging False Claims Act violations.
• The government declined to intervene in the qui tam case.
• The Company was served with the complaint on April 16, 2025, and filed a motion to dismiss in June 2025.
• No material accrual for loss contingencies associated with legal proceedings as of June 30, 2025, as an unfavorable outcome is not deemed probable and reasonably estimable.

Stakeholder Impact

• Shareholders: Significant net loss and impairment charges negatively impact equity value. New debt facility provides liquidity but adds leverage. Potential for future dilution from equity awards.
• Employees: Stock-based compensation plans continue, including new inducement awards for key personnel. 'Great Place to Work Certification' suggests positive employee environment.
• Customers/Patients: Continued development and launch of new molecular tests (FirstGene, Precise MRD) aim to improve patient care.
• Payors: UnitedHealthcare's policy change negatively impacts revenue from GeneSight test, indicating ongoing challenges with reimbursement.
• Creditors: New Credit Facility provides security for lenders with substantially all company assets. Compliance with revenue covenants is critical.

Next Steps

• Continue to monitor for any additional indicators of impairment in future periods.
• Evaluate the impact of ASU 2023-09 on income tax disclosures.
• Evaluate the impact of adopting ASU 2024-03.
• Continue to monitor developments and assess any future implications of the One Big Beautiful Bill Act.
• Make scheduled principal payments on the new Credit Facility commencing September 30, 2029.
• Comply with a minimum trailing twelve-month revenue test under the new Credit Facility, commencing December 31, 2025.

Key Dates

Recommendation

The company reported a substantial net loss of $330.5 million for the quarter, primarily due to a $316.7 million impairment charge on goodwill and intangible assets. This impairment reflects a significant decline in the perceived value of key business units (Pharmacogenomics and Women's Health) and downward revisions to forecasts, indicating fundamental challenges. While the company secured a new $200 million credit facility, this adds to debt and is largely used to refinance existing obligations. Furthermore, a key product, GeneSight, continues to face revenue headwinds due to adverse coverage changes from a major insurer. Despite some positive developments in new product launches and R&D, the magnitude of the financial deterioration and ongoing operational challenges suggest a negative outlook for the stock.

Keywords

Myriad Genetics, MYGN, molecular diagnostics, genetic testing, precision medicine, hereditary cancer, tumor profiling, prenatal testing, pharmacogenomics, GeneSight, SEC filing, 10-Q, financial results, impairment, healthcare, biopharma services, circulating tumor DNA, MRD